Selective Breath Sensors for Metabolic Monitoring

2021 ◽  
Vol MA2021-01 (62) ◽  
pp. 1647-1647
Author(s):  
Andreas T. Guntner ◽  
Philipp A. Gerber ◽  
Sotiris E. Pratsinis
Keyword(s):  
Metabolic Monitoring

scholarly journals Minding metabolism: targeted interventions to improve cardio-metabolic monitoring across early and chronic psychosis

2021 ◽  
Author(s):  
John R. Kelly ◽  
Priyola Gounden ◽  
Aoibheann McLoughlin ◽  
Zahra Legris ◽  
Therese O’Carroll ◽  
...  
Keyword(s):  
Targeted Interventions ◽  
Metabolic Monitoring ◽  
Chronic Psychosis

Nurse-assessed metabolic monitoring: A file audit of risk factor prevalence and impact of an intervention to enhance measurement of waist circumference

2014 ◽  
Vol 23 (3) ◽  
pp. 252-256 ◽  
Author(s):  
Simon Rosenbaum ◽  
Sukh Nijjar ◽  
Andrew Watkins ◽  
Natasha Garwood ◽  
Catherine Sherrington ◽  
...  
Keyword(s):  
Risk Factor ◽  
Waist Circumference ◽  
Metabolic Monitoring ◽  
Risk Factor Prevalence

scholarly journals Metabolomic adaptations and correlates of survival to immune checkpoint blockade

2019 ◽  
Vol 10 (1) ◽  
Author(s):  
Haoxin Li ◽  
Kevin Bullock ◽  
Carino Gurjao ◽  
David Braun ◽  
Sachet A. Shukla ◽  
...  
Keyword(s):  
Immune Checkpoint ◽  
Checkpoint Inhibitors ◽  
Resistance Mechanism ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Adaptive Resistance ◽  
Metabolic Monitoring ◽  
Pd1 Blockade ◽  
To Receive ◽  
Cell Death Protein

Abstract Despite remarkable success of immune checkpoint inhibitors, the majority of cancer patients have yet to receive durable benefits. Here, in order to investigate the metabolic alterations in response to immune checkpoint blockade, we comprehensively profile serum metabolites in advanced melanoma and renal cell carcinoma patients treated with nivolumab, an antibody against programmed cell death protein 1 (PD1). We identify serum kynurenine/tryptophan ratio increases as an adaptive resistance mechanism associated with worse overall survival. This advocates for patient stratification and metabolic monitoring in immunotherapy clinical trials including those combining PD1 blockade with indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase   (IDO/TDO) inhibitors.

scholarly journals INDIRECT CALORIMETRY AS AN OBJECTIVE TECHNIQUE FOR ASSESSING ENERGY NEEDS OF PATIENTS IN CRITICAL STATES

2020 ◽  
Vol 23 (6) ◽  
pp. 329-334
Author(s):  
E. S. Glebova ◽  
E. V. Ivanova-Davidova ◽  
Valery G. Amcheslavsky
Keyword(s):  
Clinical Trials ◽  
Intensive Care ◽  
Clinical Practice ◽  
Indirect Calorimetry ◽  
Narrow Range ◽  
Published Data ◽  
Pediatric Practice ◽  
Metabolic Monitoring ◽  
Energy Needs ◽  
Current Calculation

Background. Nutrition is one of the most important aspects of intensive care. While working over the nutritive program, one should take into account patient’s energy needs, which lie in a narrow range - to avoid under- or overfeeding. Purpose. To compare modern approaches to metabolic rate assessment in patients in ICU and to find the most effective one. Material and methods. The researchers have analyzed published data of clinical trials on metabolic monitoring in Russia and abroad. Results. After the scientific articles had been analyzed, it became evident that current calculation approaches cannot be considered reliable in pediatric clinical practice, especially in ICU. Thus, the indirect calorimetry, as an objective technique for calculating energy needs in patients, should be used in pediatric practice.

Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.

1993 ◽  
Vol 11 (11) ◽  
pp. 2101-2111 ◽  
Author(s):  
R L Wahl ◽  
K Zasadny ◽  
M Helvie ◽  
G D Hutchins ◽  
B Weber ◽  
...  
Keyword(s):  
Glucose Metabolism ◽  
Tumor Size ◽  
Fdg Pet ◽  
Tumor Diameter ◽  
Breast Cancers ◽  
Tumor Uptake ◽  
Influx Rate ◽  
Metabolic Monitoring ◽  
Positron Emission ◽  
Pet Scans

PURPOSE We assessed the feasibility of noninvasive metabolic monitoring of cancer chemohormonotherapy using sequential quantitative positron emission tomographic (PET) scans of tumor glucose metabolism with the glucose analog 2-[18F]-fluoro-2-deoxy-D-glucose (FDG). PATIENTS AND METHODS Eleven women with newly diagnosed primary breast cancers larger than 3 cm in diameter beginning a chemohormonotherapy program underwent a baseline and four follow-up quantitative PET scans during the first three cycles of treatment (days 0 to 63). Tumor response was sequentially determined clinically, radiographically, and then pathologically after nine treatment cycles. RESULTS Eight patients had partial or complete pathologic responses. Their maximal tumor uptake of FDG assessed by PET decreased promptly with treatment to the following: day 8, 78 +/- 9.2% (P < .03); day 21, 68.1 +/- 7.5% (P < .025); day 42, 60 +/- 5.1% (P < .001); day 63, 52.4 +/- 4.4% (P < .0001) of the basal values. Tumor diameter did not decrease significantly during this period through 63 days. Prompt decreases in the FDG influx rate (K) from basal levels (from .019 to .014 mL/cm3/min) after 8 days of treatment (P < .02) and in the estimated rate of FDG phosphorylation to FDG-6-phosphate (k3) from .055 to .038 min-1 after 8 days of treatment (P < .02) to .029 +/- .004 min-1 at 21 days) (P < .02) were observed. Three nonresponding patients had no significant decrease in tumor uptake of FDG (81 +/- 18% of basal value), influx rate (.015 to .012 mL/cm3/min), or tumor size (81 +/- 12% of basal diameter) comparing basal versus 63-day posttreatment values. CONCLUSION Quantitative FDG PET scans of primary breast cancers showed a rapid and significant decrease in tumor glucose metabolism after effective treatment was initiated, with the reduction in metabolism antedating any decrement in tumor size. No significant decrease in FDG uptake (SUV) after three cycles of treatment was observed in the nonresponding patients. FDG PET scanning has substantial promise as an early noninvasive metabolic marker of the efficacy of cancer treatment.

scholarly journals Implantable Biosensor Arrays Based On Smart Hydrogels And Piezoresistive Sensors For Continuous Metabolic Monitoring

2011 ◽  
Vol 25 ◽  
pp. 1008-1011 ◽  
Author(s):  
M. Avula ◽  
P. Tathireddy ◽  
S. Cho ◽  
L. Rieth ◽  
J.J. Magda ◽  
...  
Keyword(s):  
Biosensor Arrays ◽  
Piezoresistive Sensors ◽  
Metabolic Monitoring

Quality prescribing in early psychosis: key pharmacotherapy principles

2021 ◽  
pp. 103985622110546
Author(s):  
James G Scott ◽  
Gemma McKeon ◽  
Eva Malacova ◽  
Jackie Curtis ◽  
Bjorn Burgher ◽  
...  
Keyword(s):  
Patient Choice ◽  
Early Psychosis ◽  
Evidence Based ◽  
Prescribing Practices ◽  
Metabolic Monitoring ◽  
Risk Benefit Assessment ◽  
Medication Risk ◽  
Long Acting ◽  
Informed Patient ◽  
Medication Choice

Objective: To present a practical, easy-to-implement clinical framework designed to support evidence-based quality prescribing for people with early psychosis. Method: Identification and explanation of key principles relating to evidence-based pharmacotherapy for people with early psychosis. These were derived from the literature, practice guidelines and clinical experience. Results: Key principles include (1) medication choice informed by adverse effects; (2) metabolic monitoring at baseline and at regular intervals; (3) comprehensive and regular medication risk–benefit assessment and psychoeducation; (4) early consideration of long-acting injectable formulations (preferably driven by informed patient choice); (5) identification and treatment of comorbid mood disorders and (6) early consideration of clozapine when treatment refractory criteria are met. Conclusions: Current prescribing practices do not align with the well-established evidence for quality pharmacotherapy in early psychosis. Adopting evidence-based prescribing practices for people with early psychosis will improve outcomes.

Sign in / Sign up

Export Citation Format

Share Document